iSpecimen

iSpecimen, Inc. operates as healthcare organization that engages in procurement of human biospecimens. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in July 2009 and is headquartered in Lexington, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iSpecimen reports improved Q1 performance, eyes growth opportunities ahead

iSpecimen's Q1 2024 earnings call highlighted improved financial performance through cost management and sales growth initiatives.
While facing challenges of lower specimen counts, the company showcased strengths in pricing power, supply efficiency, and cash position.
Opportunities lie in leveraging successful programs, exploring new markets, investing in technology, and strategic partnerships for future growth.
Overall, iSpecimen's positive outlook on operational advancements signals a commitment to sustainable growth and innovation in the healthcare sector.

iSpecimen beats revenue targets, strengthens operations for future growth

iSpecimen delivered strong Q2 2024 results, surpassing revenue targets and improving operational efficiency. The company's strategic initiatives to reduce costs, optimize workforce, and enhance supplier relationships are driving growth. While challenges like funding needs persist, iSpecimen is well-positioned for future opportunities in the healthcare specimen sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

LEXINGTON, Mass., Oct. 7, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for human biospecimens  ("iSpecimen" or the "Company"), today announced it is expanding its human biospecimen supplier network to offer increasingly comprehensive selections of whole blood, plasma and other biofluids to help accelerate the development of liquid biopsies.

iSpecimen Expands Global Biospecimen Supplier Network and Access to Human Biospecimens Needed to Help Accelerate Development of Liquid Biopsies

LEXINGTON, Mass., Sept. 14, 2021 /PRNewswire/ --  iSpecimen Inc.  (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced that it will be included in the Russell Microcap® Index, effective after the U.S. market opens on September 20, 2021, as part of the 2021 Russell indexes reconstitution.

iSpecimen Announces Inclusion in Russell Microcap® Index

LEXINGTON, Mass., Sept. 1, 2021 /PRNewswire/ --  iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced that Christopher Ianelli, MD, PhD, CEO and President of iSpecimen, will participate in the H.C.

iSpecimen to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021

LEXINGTON, Mass., Aug. 18, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for human biospecimens  ("iSpecimen" or the "Company"), today announced it has grown its cancer-related supplier network despite lockdowns, slowdowns, and sustained concern around the COVID-19 pandemic.

iSpecimen Expands Human Biospecimen Offerings for Cancer Researchers

LEXINGTON, Mass., Aug. 12, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for human biospecimens ("iSpecimen" or the "Company"), today announced that an interview with its CEO and President, Dr. Christopher Ianelli, will air on The RedChip Money Report® on Bloomberg TV, at 7 p.m.

iSpecimen Inc. Interview to Air on the RedChip Money Report® on Bloomberg TV

LEXINGTON, Mass., Aug. 10, 2021 /PRNewswire/ --  iSpecimen Inc.  (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today reported its financial results for the three-month period ended June 30, 2021.

iSpecimen Reports Second Quarter 2021 Financial Results

LEXINGTON, Mass., July 29, 2021 /PRNewswire/ --  iSpecimen   Inc.  (Nasdaq: ISPC), an online marketplace for human biospecimens ("iSpecimen" or the "Company"), today announced that it has enhanced its custom biofluids collection service to offer life sciences organizations faster delivery of urgently needed research samples.

iSpecimen Launches Enhanced Custom Collection Service

LEXINGTON, Mass., July 27, 2021 /PRNewswire/ --  iSpecimen Inc.  (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced that it will report its financial results for the second quarter ended June 30, 2021, before the market open on Tuesday, August 10, 2021.

iSpecimen to Report Second Quarter 2021 Results on August 10, 2021

Each year, researchers face substantial challenges trying to get the right specimens for research from a fragmented network of biobanks.

iSpecimen: High Growth Marketplace At A Discount

LEXINGTON, Mass., July 1, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced the closing of the issuance of an additional 337,500 shares of its common stock pursuant to the full exercise of the underwriters' over-allotment option in connection with the Company's initial public offering (the "IPO").

iSpecimen Announces Closing of Over-Allotment Option in Connection with its Initial Public Offering

LEXINGTON, Mass., June 21, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced the closing of its previously announced initial public offering of 2,250,000 shares of its common stock at a price of $8.00 per share, for gross proceeds of $18,000,000 before deducting underwriting discounts, commissions and offering expenses.

iSpecimen Announces Closing of Initial Public Offering

Lyell Immunopharma

Verve Therapeutics

The companies are Verve Therapeutics, Lyell Immunopharma, iSpecimen and Angel Oak Mortgage.

3 Biotechs Plus a Mortgage Lender Go Public Today

News for iSpecimen Stock (ISPC)